PTU - Polskie Towarzystwo Urologiczne
home page
current numbers
archival numbers
list of articles:
list przewodni/covering letter
editor
Scientific Committee
publisher
subscription
advertising
important links

THE CORRELATION BETWEEN CONCENTRATIONS OF TESTOSTERONE, DIHYDROTESTOSTERONE, ACID PHOSPHATASE ACTIVITY, ITS PROSTATIC FRACTION AND RESULTS OF THERAPY OF PATIENTS WITH PROSTATIC CARCINOMA
Article published in Urologia Polska 1988/41/4.

authors

Jan Szymanowski, Ewa Koźmińska, Stefan Zgliczyński
Z Oddziału Urologii Szpitala Bielańskiego w Warszawie
Ordynator: dr n. med. J. Szymanowski Z Kliniki Endokrynologii CMKP w Warszawie Kierownik: prof. dr hab. med. S. Zgliczyński

summary

The aim of the article is to evaluate the usefulness of determining concentra­tions of testosterone (T) and dihydrotestosterone (DHT) in the blood serum of pa­tients with prostatic carcinoma before starting therapy and also to evaluate the correlation between concentrations of T, DHT and acid phosphaase activity, its prostatic fraction and the survival time in a group of 45 patients undergoing the same therapeutic procedure. A Control group were 58 healthy men of the same age group.
Twenty-one patients (46.7'%) with an increased level of T and DHT had low phosphatase activity and long survival time.
Hormonal treatment reducing concentrations of T and DHT in patients with low initial concentrations of the hormones seems useless, especially in patients with low activity of prostatic fraction of acid phosphatase and no clinical symp- toms.

references

  1. 1. Adlercreutz H., Ranniko S., Kairento A, L,, Karonen S. L.: Hormonal pat­
  2. tern in prostatic cancer. II. Correlation with primary response to endocrine treat­
  3. ment. Acta endocr., 1981, 98, 4, 634. ? 2. Baker H.W.G., Burger H.G., De Kretser
  4. D.M., Hudson B., Rennie G.C., Straffon W.G.: The assessment of results following
  5. endocrine therapy for prostatic cancer. J. Urol., 1975, 113, 6, 824. ? 3. Baranowska
  6. B., Jeske W., Szymanowski J., Piechna K.: L'accroisement de la secretion de la pro-
  7. lactine apres le freinage des recepteurs dopaminoergiques par le metoclopramide
  8. chez les malades porteurs d'un cancer de la prostate. J. d'Urologie, 1983, 89, 8, 601.
  9. ? 4. Baranowska B., Szymanowski J., Jeske W.: Wpływ bromokryptyny na wy­
  10. dzielanie prolaktyny po zablokowaniu receptorów dopaminergicznych metoklopra­
  11. midem u chorych z rakiem gruczołu krokowego leczonych estrogenami. Endokr.
  12. Pol., 1984, 35, 4, 211. ? 5. British Prostate Study Group: Evaluation of plasma hor­
  13. mone concentrations in relation to clinical staging in patients with prostatic cancer.
  14. Brit. J. Urol., 1979, 51, 382. ? 6. Catalona W.J.: Prostate cancer. Grune, Stratton.
  15. Orlando, 1984, 7. ? 7. Fossa S.D., Host H., Aakvaag A.: Serum-Testosteronspiegel
  16. bei der hormonellen Behandlung des fortgeschrittenen Prostatakarzinoms. Akt. Urol.,
  17. 1982,43,273.8. Hickey D., Todd B., Soloway M.S.: Pre-treatment testosterone
  18. levels: significance in androgen deprivation therapy. J. Urol., 1986. 136, 5, 1038. ?
  19. 9. Jeromin L.: Metabolizm testosteronu w raku gruczołu krokowego. Urol. Pol.,
  20. 1982,35,3?4,135. ? 10. Jewett H.J.: Prostatic cancer: a personal view of the prob­
  21. lem. J. Urol., 1984. 131, 845.
  22. 11. Kirk D.: Trials and tribulations in prostatic cancer. Brit. J. Urol., 1987, 59,
  23. 375. ? 12. Leńko J.: Rak stercza. Urol. Pol.. 1984. 37. 4. 245 ? 13, Szymanowski J.:
  24. Współzależność między zaburzeniami hormonalnymi a stadium zaawansowania i
  25. stopniem złośliwości raka gruczołu krokowego. Pol. Tyg. Lek., 1983, 37, 30, 943. ?
  26. 14. Szymanowski J., Baranowska B., Niewiadomska A.. Wysocki M., Kobuszewska-
  27. -taryna M., Zgliczyński S.: L'interdependence entre les troubles hormonaux, le sta­
  28. de d'evolution et de degre de malignite du cancer de la glande prostatique. J.
  29. d'Urol., 1983, 89, 8, 597. ?15. Szymanowski J., Baranowska B., Rozbicka G., Jeske W.,
  30. Zgliczyński S.: L'interdependence entre les troubles hormonaux, le stade d'evolution
  31. et le degre de malignite du cancer de la glande prostatique. J. d'Urol.. 1983,
  32. 89. 9, 663. ? 16. Wilson D. W., Harper M. E., Jensen H. M., Ikeda R. M., Richards G ,
  33. Peeling W. B., Pierrepoint C. G., Griffiths K.: A Prognostic index for the clinical
  34. management of patients with advanced prostatic cancer: A British Prostatic Study
  35. Group investigation. Prostate, 1985, 7, 131. ? 17. Zaridze D.G., Boyle P.: Cancer
  36. of the prostate: Epidemiology and aetiology. Review. Brit. J. Urol.. 1987, 59, 493.